Cancer Therapy
Research findings from University of Pennsylvania, Abramson Cancer Center update understanding of cancer therapy
Published in Cancer Weekly, January 29th, 2008
A report, 'A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer,' is newly published data in Cancer. "The combination of a fixed dose rate (FDR) infusion of gemcitabine and irinotecan may have a synergistic effect in the treatment of patients with advanced and metastatic pancreatic and biliary cancer. The current study was conducted to determine the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of the combination," researchers in the United States report.
"There were 32 patients with metastatic pancreatic and advanced unresectable/metastatic biliary adenocarcinoma who were...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-01-29)
More Articles from Cancer Weekly
- Adenoma
Researchers from Kumamoto University detail findings in adenoma - Breast Cancer
Celsion to Proceed with Phase II Pivotal Breast Cancer Trial after Receiving Supportive FDA Response - Cancer Gene Therapy
New cancer gene therapy study results reported from H.L. Oian et al - Cancer Gene Therapy
Reports outline cancer gene therapy study results from Tohoku University, Medical Department - Cancer Vaccines
Reports from P. Nanni and co-researchers add new data to research in cancer vaccines - Cancer Vaccines
Studies from Sichuan University yield new information about cancer vaccines - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
